Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain
Creative Medical Technology received FDA clearance to expand its ADAPT trial for Olastrocel, adding a cohort of 15 patients using less than 90 mg per day of morphine equivalents. The expansion follows positive 180-day interim data showing statistically significant improvements in functional disability and pain, with the new cohort already more than 85% enrolled.
Key figures
- Phase Of Trial
- Phase 2 (expansion) / Phase 3 planning
- Expansion cohort size
- 15
- Expansion enrollment pct
- >85%
- Morphine equivalent limit
- 90 mg per day
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.